Ulixertinib for cancers with MAPK pathway changes
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial offers access to ulixertinib, an oral drug that targets specific genetic changes (MAPK pathway) in advanced cancers. It is for people who have run out of standard options and may benefit from this targeted treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor with a change (mutation) in genes like KRAS, NRAS, BRAF, MEK, or ERK.
- Your doctor agrees that standard cancer treatments are no longer working or are not enough.
- You are at least 12 years old.
- You must be able to swallow and keep down oral medicine.
- You cannot have had certain stomach or intestine surgeries that affect how the drug is absorbed.
- If you are a woman who can get pregnant, you need a negative pregnancy test and must use effective birth control during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, ulixertinib and palbociclib, taken together to see if they can shrink tumors in patients with advanced pancreatic cancer, melanoma, or other solid tumors. It may be an option for people who have already tried standard treatments.
This trial tests a new drug, KIN-2787, for people with advanced solid tumors that have specific changes (mutations) in the BRAF or NRAS genes. The drug is designed to target these changes and may help shrink or control the tumor.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This Phase 1 trial tests a combination of targeted cancer medicines to treat melanoma that has spread or cannot be removed by surgery. It is for people whose tumor has a specific BRAF mutation, and who have either stayed stable on a prior targeted treatment or no longer respond to it.
This study tests if giving you targeted therapy pills (encorafenib and binimetinib) only when a blood test shows your cancer is active — instead of continuously — can help keep the melanoma under control with fewer side effects. It is designed for people with advanced melanoma that has a BRAF mutation.
This trial studies how well cabozantinib works in advanced lung cancer when the tumor has certain gene changes (like RET, ROS1, NTRK, MET, or AXL). It may help slow tumor growth after standard treatments, depending on your tumor test results.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.